Ximelagatran

Aka: Ximelagatran, Exanta, Exarta

advertisement

II. Background

  1. No longer available (off market in U.S.) due to hepatotoxicity
  2. Listed for historical reasons only

III. Mechanism

  1. Direct Thrombin Inhibitor

IV. Indications: Non-Valvular Atrial Fibrillation

  1. Warfarin intolerant
  2. Patients with high risk of Intracranial Hemorrhage

V. Advantages

  1. As effective as Warfarin with INR 2-3
  2. Ximelagartan does not require monitoring
  3. Ximelagartan has fewer bleeding complications

VI. Disadvantages

  1. Expensive
  2. Myocardial Ischemia risk
  3. Risk of severe liver toxicity

VII. Dosing

  1. Studies used fixed dose of 36 mg bid

VIII. References

  1. Albers (2005) JAMA 293:690-8 [PubMed]
  2. Olsson (2003) Lancet 362:1691-8 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Ximelagatran." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Ontology: ximelagatran (C0966370)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C426686
SnomedCT 415853004
English xi-melagatran, XIMELAGATRAN, ximelagatran [Chemical/Ingredient], Ximelagatran (substance), Ximelagratan, Ximelagratan (substance), Ximelagatran, glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester, glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester, ximelagatran
Spanish ximelagatrán, ximelagatrán (sustancia), ximelagratan, ximelagratan (sustancia)
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

advertisement

2020 Family Practice Notebook, LLC. Terms | Privacy (EHS) | About | Site Map | Blog

Footer Site Logo